Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/29/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
03/29/2023* -- Results Q4 2022 -- -0.30 --
08/09/2022 -- Results Q2 2022 -0.15 -0.30 50.00%
05/16/2022 -- Results Q1 2022 -0.30 -0.30 0.00%
03/29/2022 16:30 EST Earnings Call Q4 2021 -- -- --
03/29/2022 -- Results Q4 2021 -0.60 -0.30 -100.0%
11/10/2021 16:30 EST Earnings Call Q3 2021 -- -- --
11/10/2021 -- Results Q3 2021 -0.30 -0.30 0.00%
*Estimated Date/Time

Earnings

Next Report Date 03/29/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/09/2022
Beat/Miss Upgrade
Return Since -76.07%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Its lead product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19 induced respiratory distress.
URL https://www.ampiopharma.com
Investor Relations URL http://ampiopharma.com/investors/stock-information/
HQ State/Province Colorado
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 29, 2023 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
2.04%
-67.38%
352.1%
-90.30%
47.67%
172.7%
-64.15%
-95.96%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-84.33%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-68.65%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-87.61%
56.85%
-66.70%
-33.39%
-96.85%
-9.48%
-24.44%
-28.93%
-73.55%
As of December 02, 2022.

Profile

Edit
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and advancement of immunomodulatory therapies for the treatment of pain from osteoarthritis. Its lead product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19 induced respiratory distress.
URL https://www.ampiopharma.com
Investor Relations URL http://ampiopharma.com/investors/stock-information/
HQ State/Province Colorado
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 29, 2023 (est.)
Last Earnings Release Aug. 09, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter AMPE Tweets